Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628485 | 0.85 | FLT1 (0.52) | VCAM1FLT1FLT4KDRLMNA | |
| SCHEMBL2225438 | 0.85 | ALDH1A1 (0.57) | VCAM1PPARGFLT1FLT4KDR | |
| SCHEMBL30818930 | 0.83 | CASP1 (0.55) | VCAM1PPARGFLT1FLT4KDR | |
| SCHEMBL3211886 | 0.83 | CASP1 (0.55) | VCAM1PPARGFLT1FLT4KDR | |
| SCHEMBL30819065 | 0.81 | PPARG (0.51) | VCAM1PPARGFLT1FLT4KDR | |
| SCHEMBL282483 | 0.79 | ALDH1A1 (0.47) | FLT1FLT4KDRLMNAMAPT | |
| SCHEMBL7951890 | 0.79 | TTR (0.39) | VCAM1FLT1FLT4KDRLMNA | |
| SCHEMBL26582862 | 0.79 | FFAR1 (0.41) | FLT1FLT4KDRMAPTPDK1 | |
| SCHEMBL3820471 | 0.79 | SMN1; SMN2 (0.50) | VCAM1PPARGFLT1FLT4KDR | |
| SCHEMBL1179997 | 0.79 | MEN1 (0.49) | VCAM1PPARGFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653053-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4426434-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-12 | — | — | US | disclosed |
| CN-119677720-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-03-13 | — | — | US | disclosed |
| CN-119585237-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4489863-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4490147-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-118984823-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-3724165-B1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA S L (ES) | 2022-01-12 | — | — | EP | disclosed |
| EP-3724165-B1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA S L (ES) | 2022-01-12 | — | — | EP | disclosed |
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3724165-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2020-10-21 | — | — | EP | disclosed |
| CN-111630030-A | Novel benzamide derivatives as PPAR-gamma modulators | 梅迪比奥法尔玛公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2019115498-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019115498-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-20 | — | — | WO | disclosed |
| EP-3498694-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-19 | — | — | EP | disclosed |
| EP-3498694-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171511-A1 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS | PPARD, PPARG, PPARA | VCAM1 1764/4885PPARG 2/4885FLT1 1142/4885 |
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | VCAM1 3601/4885PPARG 1/4885FLT1 1526/4885 |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | VCAM1 3638/4885PPARG 1/4885FLT1 1520/4885 |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | VCAM1 3601/4885PPARG 1/4885FLT1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.